The Device That Acts Like a Drug: Alpha Tau's Secret Weapon in Cancer Care (NASDAQ: DRTS)

Alpha Tau (NASDAQ: DRTS), A medical device company is pursuing pharma-style returns with a technology that delivers targeted radiation directly inside tumors. Recent FDA approvals for combination cancer therapies signal accelerating market acceptance for Alpha Tau’s hybrid approach.

In oncology investing, companies typically fall into clear categories: those developing systemic drugs that treat cancer throughout the body, or those creating medical devices for localized treatment. Alpha Tau Medical (NASDAQ: DRTS) represents something different entirely.

The Israeli company has developed Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), a treatment that implants tiny radioactive sources directly into tumors. When the radium-224 decays, it releases alpha particles that destroy cancer cells within a few millimeters while leaving surrounding healthy tissue largely unaffected.

This approach creates an unusual hybrid: a medical device that delivers drug-like efficacy with precise targeting that traditional systemic therapies cannot achieve.

Clinical Results Drive Interest

Recent trial data suggests this hybrid approach may be yielding results. In pancreatic cancer studies across Israel and Canada, Alpha DaRT achieved over 90% disease control rates in 41 patients, according to data presented at the 2025 ASCO GI Symposium. Pancreatic cancer is widely recognized as one of the most challenging cancers to treat.

Even more notable were results from a combination study in Israel. When Alpha DaRT was paired with pembrolizumab (Keytruda) in eight patients with recurrent head and neck cancer, the combination produced a 75% systemic objective response rate and 37.5% complete response rate. This compares to historical response rates of 19% and 5% respectively for pembrolizumab alone in similar patient populations.

The mechanism behind these enhanced responses when Alpha DaRT is combined with immunotherapy appears related to the localized radiation creating an immune response that extends beyond the treated tumor site.

Market Timing Favors Combination Approaches

Alpha Tau’s combination-friendly technology arrives as the oncology market increasingly validates multi-modal treatment approaches. Recent FDA approvals underscore this trend. In June 2025, the FDA approved Keytruda for head and neck cancer in a complex regimen combining immunotherapy with radiotherapy, demonstrating regulatory acceptance of sophisticated combination protocols.

Similarly, Trethera Corporation received Fast Track designation for combining its novel therapy with radiopharmaceuticals, further validating the combination approach that Alpha DaRT is positioned to leverage across multiple cancer types.

Recent Corporate Milestones

Alpha Tau marked two significant developments in April 2025. The company received FDA approval for an Investigational Device Exemption to conduct a pilot study in patients with recurrent glioblastoma multiforme (GBM), one of the most aggressive forms of brain cancer with an average survival rate of only eight months.

The GBM study represents Alpha Tau’s entry into brain cancer treatment, building on the FDA’s previous Breakthrough Device Designation for this indication. The clinical trial will enroll up to ten patients with recurrent glioblastoma not suitable for surgical removal.

Later in April, the company closed a $36.9 million strategic investment from Oramed Pharmaceuticals, with Oramed’s CEO Nadav Kidron joining Alpha Tau’s board. Kidron described Alpha DaRT as “a truly groundbreaking medical technology” and expressed “unwavering confidence in the exceptional potential of the Alpha DaRT technology platform.”

Regulatory Pathway Advantages

Unlike pharmaceutical companies navigating decade-long drug development timelines, Alpha Tau is pursuing the medical device regulatory pathway. The company currently holds four active Investigational Device Exemptions (IDEs) from the FDA covering skin cancer, head and neck cancer, pancreatic cancer, and glioblastoma.

Alpha Tau’s Jerusalem manufacturing facility recently achieved MDSAP (Medical Device Single Audit Program) certification, allowing a single audit to satisfy regulatory requirements across the US, Canada, Australia, Japan, and Brazil simultaneously.

Platform Potential and Valuation Gap

Alpha Tau’s current market capitalization sits around $265 million, modest compared to recent radiotherapy acquisitions. Bristol Myers Squibb acquired RayzeBio for approximately $4.1 billion in 2023, while AstraZeneca paid $2.1 billion for Fusion Pharmaceuticals, both developing different targeted radiation approaches.

The platform nature of Alpha DaRT allows the company to pursue multiple cancer types simultaneously, with current programs spanning skin cancers, head and neck tumors, pancreatic cancer, and brain tumors.

Potential Near-Term Catalysts

Alpha Tau faces several potential inflection points. Japan’s PMDA is reviewing the company’s marketing application for head and neck cancer, with a decision expected in H2 2025. In the US, the company expects to begin treating patients in its pancreatic cancer pilot study in Q3 2025, with the glioblastoma pilot launching in H2 2025.

With $83.3 million in cash as of Q2 2025, Alpha Tau has runway to advance clinical programs while building commercial infrastructure. However, the company remains clinical-stage with inherent development risks.

For investors seeking exposure to novel cancer approaches, Alpha Tau offers a differentiated model combining device precision with broad therapeutic applicability, positioned at the intersection of an increasingly combination-focused oncology market.